Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ≥ 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)

NCT05633355 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT05633355
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05633355 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-label, 52-week Study to Assess the Safety, Tolerability, and Efficacy of Rocatinlimab (AMG 451) in Adolescent Subjects Aged ≥ 12 to < 18 Years With Moderate-to-severe Atopic Dermatitis (AD) (ROCKET-Orbit)
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
January 30, 2023
Completion date
July 31, 2025
Enrollment
187 (actual)
Sites
77

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis